Image courtesy: Bharat Biotec

The All India Institute of Medical Sciences (AIIMS), New Delhi will begin human trials of India’s first indigenous COVID-19 vaccine, Covaxin, from next week on 100 healthy volunteers aged between 18 and 55 years.

The volunteers will be kept under observation for a period of nearly 150 days.

Covaxin is developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).

According to Bharat Biotech, the Phase 1 clinical trial for Covaxin has been initiated across the country from July 15 onwards, and this is a randomized, double-blind, placebo-controlled clinical trial on 375 volunteers across the country.

AIIMS has also set up a dedicated e-mail and phone number for the volunteers to register themselves for this project.

The volunteers will have to undergo tests, which include COVID-19 test and also tests for other comorbidities.

If found healthy, they will be administered the vaccine.

Also read: Clinical trial of COVID-19 vaccine begins

According to a senior official, recently the ethics committee has given a go-ahead for human trials for the vaccine, and AIIMS will begin registering volunteers as per the procedure.

Volunteers willing to register for human trials can email at

On Friday, Haryana Health Minister Anil Vij had said that human trial of a vaccine against novel coronavirus has begun at the Post Graduate Institute of Medical Sciences in Rohtak.

The SARS-CoV-2 strain was isolated in NIV, Pune, and transferred to Bharat Biotech.

The indigenous, inactivated vaccine was developed and manufactured in Bharat Biotech’s BSL-3A (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad.

The Drug Controller General of India, Central Drugs Standard Control Organisation (CDSCO), and the Ministry of Health & Family Welfare granted permission to initiate Phase-I and II human clinical trials after the company submitted results generated from pre-clinical studies, demonstrating safety and immune response.


Northeast Now is a multi-app based hyper-regional bilingual news portal. Mail us at: